Expert Opinion on Therapeutic Patents · 2001 · 21 citations · 45 references
MedicineMedicinal ChemistryPharmacologyCell SignalingDrug DiscoveryMolecular PharmacologyDrug-receptor InteractionsLigand BindingPeptide ChemistryReceptor BindingReceptor PharmacologyReceptor-ligand InteractionsLigand Design For ReceptorsMelanocortin SignalingMelanocortin SystemOverviewPeptide Medicinal ChemistryReceptor-ligand BindingReceptors
This review will give a brief overview of the pharmacology of the melanocortin receptors (MCRs) as a background. The review will not handle the patents or patent applications dealing with cloning of the different subtypes of the receptor, since this has been recently reviewed [1]. This review will focus on different ligands acting either as agonists or antagonists to the different subtypes of the receptor, i.e., MC1R, MC3R, MC4R and MC5R. Just recently a number of patent applications have reached the public domain, which describe small peptides or low molecular weight organic compounds binding and acting on the MCRs.
45
Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice
Dennis Huszar, Catherine Lynch, Victoria Fairchild-Huntress et al. · Cell · 1997 · 3K citations · Full text
Role of melanocortinergic neurons in feeding and the agouti obesity syndrome
Wei Fan, Bruce A. Boston, Robert A. Kesterson et al. · Nature · 1997 · 1.9K citations
The Cloning of a Family of Genes That Encode the Melanocortin Receptors
Kathleen G. Mountjoy, Linda S. Robbins, Marty Mortrud et al. · Science · 1992 · 1.6K citations